Maioli Tatiani Uceli, Borras-Nogues Esther, Torres Licia, Barbosa Sara Candida, Martins Vinicius Dantas, Langella Philippe, Azevedo Vasco Ariston, Chatel Jean-Marc
Departamento de Nutrição, Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Université Paris Saclay, INRAE, AgroParisTech, Micalis, Jouy-en-Josas, France.
Front Pharmacol. 2021 Dec 2;12:740636. doi: 10.3389/fphar.2021.740636. eCollection 2021.
Metabolic disorders are an increasing concern in the industrialized world. Current research has shown a direct link between the composition of the gut microbiota and the pathogenesis of obesity and diabetes. In only a few weeks, an obesity-inducing diet can lead to increased gut permeability and microbial dysbiosis, which contributes to chronic inflammation in the gut and adipose tissues, and to the development of insulin resistance. In this review, we examine the interplay between gut inflammation, insulin resistance, and the gut microbiota, and discuss how some probiotic species can be used to modulate gut homeostasis. We focus primarily on , a highly abundant butyrate-producing bacterium that has been proposed both as a biomarker for the development of different gut pathologies and as a potential treatment due to its production of anti-inflammatory metabolites.
代谢紊乱在工业化国家日益受到关注。目前的研究表明，肠道微生物群的组成与肥胖和糖尿病的发病机制之间存在直接联系。仅在几周内，诱导肥胖的饮食就会导致肠道通透性增加和微生物失调，这会导致肠道和脂肪组织的慢性炎症，并导致胰岛素抵抗的发展。在这篇综述中，我们研究了肠道炎症、胰岛素抵抗和肠道微生物群之间的相互作用，并讨论了一些益生菌物种如何用于调节肠道稳态。我们主要关注[具体细菌名称]，这是一种高度丰富的产丁酸细菌，它既被提议作为不同肠道疾病发展的生物标志物，又因其产生抗炎代谢物而被视为一种潜在的治疗方法。
